Literature DB >> 20206383

Bcr-Abl-independent mechanism of resistance to imatinib in K562 cells: Induction of cyclooxygenase-2 (COX-2) by histone deacetylases (HDACs).

Arunasree M Kalle1, Sachchidanand Sachchidanand, Reddanna Pallu.   

Abstract

Our previous studies have shown that overexpression of MDR1 and cyclooygenase-2 (COX-2) resulted in resistance development to imatinib in chronic myelogenous leukemia (CML) K562 (IR-K562) cells. In the present study, the regulatory mechanism of MDR1 induction by COX-2 was investigated. A gradual overexpression of MDR1 and COX-2 during the process of development was observed. Furthermore, down regulation of MDR1 upon COX-2 knockdown by siRNA showed a decrease in the PKC levels and activation of PKC by addition of PGE(2) to K562 cells, suggesting a role for PKC in the COX-2 mediated induction of MDR1. The present study demonstrates COX-2 induction by HDACs and MDR1 induction by COX-2 via PGE(2)-cAMP-PKC-mediated pathway. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20206383     DOI： 10.1016/j.leukres.2010.01.030

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  8 in total

1.  Aberrant DNA methylation at HOXA4 and HOXA5 genes are associated with resistance to imatinib mesylate among chronic myeloid leukemia patients.

Authors:  Marjanu Hikmah Elias; Husin Azlan; Sarina Sulong; Abdul Aziz Baba; Ravindran Ankathil
Journal:  Cancer Rep (Hoboken)       Date:  2018-07-27

2.  Inhibition of bacterial multidrug resistance by celecoxib, a cyclooxygenase-2 inhibitor.

Authors:  Arunasree M Kalle; Arshad Rizvi
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

Review 3.  Deactylase inhibition in myeloproliferative neoplasms.

Authors:  Sridurga Mithraprabhu; George Grigoriadis; Tiffany Khong; Andrew Spencer
Journal:  Invest New Drugs       Date:  2010-12-03       Impact factor: 3.850

4.  Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells.

Authors:  J Wang; T P Hughes; C H Kok; V A Saunders; A Frede; K Groot-Obbink; M Osborn; A A Somogyi; R J D'Andrea; D L White
Journal:  Br J Cancer       Date:  2012-04-24       Impact factor: 7.640

Review 5.  Role of calcium-dependent protein kinases in chronic myeloid leukemia: combined effects of PKC and BCR-ABL signaling on cellular alterations during leukemia development.

Authors:  André L Mencalha; Stephany Corrêa; Eliana Abdelhay
Journal:  Onco Targets Ther       Date:  2014-07-08       Impact factor: 4.147

6.  The inhibitory effect of pseudolaric acid B on gastric cancer and multidrug resistance via Cox-2/PKC-α/P-gp pathway.

Authors:  Qian Sun; Yan Li
Journal:  PLoS One       Date:  2014-09-24       Impact factor: 3.240

7.  Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the State of Qatar.

Authors:  Mohamed A Ismail; Muthanna Samara; Ali Al Sayab; Mohamed Alsharshani; Mohamed A Yassin; Govindarajulu Varadharaj; Marzia Vezzalini; Luisa Tomasello; Maria Monne; Hisham Morsi; M Walid Qoronfleh; Hatem Zayed; Richard Cook; Claudio Sorio; Helmout Modjtahedi; Nader I Al-Dewik
Journal:  Mol Genet Genomic Med       Date:  2020-07-23       Impact factor: 2.183

Review 8.  Selective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing.

Authors:  Afaf A El-Malah; Magdy M Gineinah; Pran Kishore Deb; Ahdab N Khayyat; Monika Bansal; Katharigatta N Venugopala; Anfal S Aljahdali
Journal:  Pharmaceuticals (Basel)       Date:  2022-07-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.